Sign In
Buy NKGN
$0.0600
+0 (+0%)
At Close: Jun 03, 2026
NKGN Stock Alert: The Alzheimer's News That Has NKGen Biotech Soaring Today
11:41am, Monday, 20'th May 2024
NKGen Biotech (NASDAQ: NKGN ) stock is taking off on Monday after the clinical-stage biotechnology company got an update on its Phase 2 clinical trial. The company says that its Safety Review Committe
NKGen Biotech's SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer's Disease
08:05am, Monday, 20'th May 2024
SNK01, a cryopreserved, autologous enhanced natural killer cell therapy, delivered in highest dose to date, demonstrates preliminary clinical benefit without any drug-related adverse events.
SANTA ANA, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commerc
NKGen advances its neurodegenerative disease program with FDA IND clearance for its Phase 1/2a SNK01 Clinical Trial in patients with Parkinson's disease.
In vitro studies with SNK01 have shown a direct ability to phagocytose and digest amyloid and alpha-synuclein proteins while also secreting immunoregulatory cytokines and identifying and eliminating a
NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
04:45pm, Wednesday, 24'th Apr 2024
SANTA ANA, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and comme
SANTA ANA, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and comme
NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs
08:05am, Thursday, 11'th Apr 2024
The Company's neurodegenerative clinical program remains on track, with continued advancement of the Alzheimer's Phase 2 trial and anticipation of Parkinson's Phase 1/2a trial initiation.
NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer's Disease at the Tau2024 Global Conference
04:05pm, Monday, 25'th Mar 2024
SNK01 autologous NK cell therapy demonstrated a positive effect on cerebral spinal fluid (“CSF”) and plasma Tau proteins in Alzheimer's patients.
Why Is NKGen Biotech (NKGN) Stock Up 62% Today?
07:52am, Wednesday, 06'th Mar 2024
NKGen Biotech (NASDAQ: NKGN ) stock is soaring higher on Wednesday alongside heavy pre-market trading of the clinical-stage biotechnology company's shares. This has more than 6 million shares of NKGN
NKGen Biotech Announces Upcoming Presentation on SNK01 in Alzheimer's Disease at the Tau2024 Global Conference
08:00am, Monday, 04'th Mar 2024
SANTA ANA, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and comme
NKGen Biotech's autologous clinical program product candidate, SNK01, demonstrated improvement in neuroinflammation and cognitive function in patients with Alzheimer's Disease (“AD”) in its Phase
NKGen Biotech Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer's Disease
08:00am, Wednesday, 27'th Dec 2023
NKGen's SNK01 program continues to show positive progress with the FDA IND clearance in October 2023, and now the CTA clearance by Health Canada for a phase 1/2a clinical trial in moderate Alzheimer's
NKGen Biotech, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights
04:48pm, Tuesday, 14'th Nov 2023
– SNK01 Phase I autologous clinical program demonstrated improvement in neuroinflammation and cognitive function in patients with Alzheimer's Disease, expect to initiate Phase I/IIa by year end
Why Is NKGen Biotech (NKGN) Stock Up 18% Today?
07:50am, Friday, 27'th Oct 2023
NKGen Biotech (NASDAQ: NKGN )) stock is taking off on Friday with continued growth after announcing clinical trial results yesterday. Those clinical trial results covered SNK01.
